| 2026-08-13 | Press release | PDF Version · Q2 2026 |
| 2026-08-13 | Press release | Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 |
| 2026-08-13 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-13 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-06-10 | Deck | Investor presentation · Jun 2026 |
| 2026-05-27 | Deck | Investor presentation · May 2026 |
| 2026-05-27 | Press release | PDF Version |
| 2026-05-27 | Press release | Aktis Oncology to Present at the Jefferies Global Healthcare Conference |
| 2026-05-21 | Press release | PDF Version |
| 2026-05-21 | Press release | Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake |
| 2026-05-11 | Press release | PDF Version · Q1 2026 |
| 2026-05-11 | Press release | Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 |
| 2026-05-11 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-11 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-06 | Press release | PDF Version |
| 2026-05-06 | Press release | Aktis Oncology to Present at the BofA Securities Health Care Conference |
| 2026-05-05 | Deck | Investor presentation · May 2026 |
| 2026-05-04 | Press release | PDF Version |
| 2026-05-04 | Press release | Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castrat |
| 2026-04-21 | Press release | PDF Version |
| 2026-04-21 | Press release | Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Soc |
| 2026-04-16 | Press release | PDF Version |
| 2026-04-16 | Press release | Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors |
| 2026-04-16 | 8-K | Form 8-K, Item 5.02 |
| 2026-03-30 | Press release | PDF Version · FY 2025 |
| 2026-03-30 | Press release | Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updat · FY 2025 |
| 2026-03-30 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-30 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-03-02 | Deck | Investor presentation · Mar 2026 |
| 2026-02-24 | Press release | PDF Version |
| 2026-02-24 | Press release | PDF Version |
| 2026-02-24 | Press release | Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate |
| 2026-02-24 | Press release | Aktis Oncology to Present at Upcoming March Investor Conferences |
| 2026-01-13 | Press release | PDF Version |
| 2026-01-13 | Press release | Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchas |
| 2026-01-12 | 8-K | Form 8-K, Item 5.03 |
| 2026-01-08 | Press release | PDF Version |
| 2026-01-08 | Press release | Aktis Oncology Announces Pricing of its Upsized Initial Public Offering |
| 2026-01-07 | SEC filing | Form S-1/A |
| 2026-01-05 | SEC filing | Form S-1/A |